All In Biotech

Drug Trial Radar · NCT05270044

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group

Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 815 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

815

Planned (sponsor's estimate)

Start

May 2, 2022

Primary completion

Mar 31, 2027

Study completion May 2, 2035

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).

Conditions

  • Melanoma

Interventions

  • Encorafenib and BinimetinibDrug

    Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.

  • Placebo to match Encorafenib ; Placebo to match BinimetinibDrug

    Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survival (RFS)Time frame: Approximately 4.4 years from the accrual of the first patient.

Locations

155 sites in 23 countries. Site status is shown where the registry gives one.

  • Hospital Aleman

    Ciudad Autonoma Buenos Aires, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Ciudad Autonoma Buenos Aires, Argentina

  • Clinica Adventista Belgrano

    Ciudad Autonoma Buenos Aires, Argentina

  • Centro Oncologico Korben

    CABA, Buenos Aires, Argentina

  • Centro de Investigaciones Medicas Mar del Plata

    Mar del Plata, Buenos Aires, Argentina

  • Fundacion CIDEA

    Ciudad Autonoma Bs As, Ciudad Autonoma Buenos Aires, Argentina

  • Sanatorio Britanico S.A.

    Rosario, Santa Fe Province, Argentina

  • Instituto de Oncologia de Rosario

    Rosario, Santa Fe Province, Argentina

  • Westmead Hospital

    Sydney, New South Wales, Australia

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Adelaide Oncology & Haematolog, Calvary North Adelaide Hospital

    North Adelaide, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • The Alfred Hospital

    Prahran, Victoria, Australia

  • Hollywood Private Hospital

    Nedlands, Western Australia, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Landeskrankenhaus - Universitaetsklinikum Graz

    Graz, Austria

  • Krankenhaus der Elisabethinen Linz

    Linz, Austria

  • Universitätsklinikum St.Pölten-Lilienfeld

    Sankt Pölten, Austria

  • AKH - Medizinische Universität Wien

    Vienna, Austria

  • Institut Jules Bordet

    Anderlecht, Belgium

  • ZNA Middelheim

    Antwerp, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • ZNA

    Merksem, Belgium

  • Vitaz

    Sint-Niklaas, Belgium

  • CHU UCL Namur

    Yvoir, Belgium

  • AMO - Assistência Multidisciplinar em Oncologia

    Salvador, Estado de Bahia, Brazil

  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer

    Curitiba, Paraná, Brazil

  • Instituto de Cancer de Londrina

    Londrina, Paraná, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • HGB - Hospital Giovanni Battista - Mãe de Deus Center

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto de Oncologia Saint Gallen

    Santa Cruz do Sul, Rio Grande do Sul, Brazil

  • CEPON - Centro de Pesquisas Oncológicas de Santa Catarina

    Florianópolis, Santa Catarina, Brazil

  • Fundação Doutor Amaral Carvalho

    Jaú, São Paulo, Brazil

  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

    Santo André, São Paulo, Brazil

  • A. C. Camargo Cancer Center

    São Paulo, São Paulo, Brazil

  • London Health Sciences Centre (LHSC) - Victoria Hospital

    London, Ontario, Canada

Showing 40 of 155 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.